Analisis Strategi Penerapan Sistem Manajemen Keamanan Pangan HACCP (Hazard Analysis and Critical Control Points) Di PT. Sierad Produce Tbk. Parung

Quality and safety food products problem was usually after thought in the food industry development issues, accordance with the consumer\u27s desirability that understand the importance of product quality and food safety. Hazard Analysis and Critical Control Points (HACCP) certification is one way for company to implementing food safety. Sierad Produce Corp. at this moment has obtained HACCP certificate to produce chicken carcasses.But the implementation need to be controlled, as the case of foodborne illness and foodborne disease can occur easily if not properly controlled. The main objective of this research is to develop the best strategy to implement HACCP and to maintain the food safety quality system at Sierad Produce Corp. The information and data that has been collected within this research were covering both the primary and secondary data based on the date of September 2012 to December 2012. The methods used in this research are descriptive analysis, Internal Factor Evaluation (IFE), External Factor Evaluation (EFE), Internal External (IE), Strength Weakness Opportunity Threat (SWOT) and Analysis Hierarchy Process (AHP). Based on this research, the best strategy for implementing HACCP and sustain the system on Sierad Produce are Critical Control Points (CCP) evaluation and improvement of production room

The Expression and Prognostic Roles of MCMs in Pancreatic Cancer

<div><p>Objectives</p><p>Minichromosome maintenance (MCM) proteins play important roles in DNA replication by interacting with other factors which participate in the regulation of DNA synthesis. Abnormal over-expression of MCMs was observed in numerous malignancies, such as colorectal cancer. However, the expression of MCMs in pancreatic cancer (PC) was less investigated so far. This study was designed to analyze the expression and prognostic roles of MCM1-10 in PC based on the data provided by The Cancer Genome Atlas (TCGA).</p><p>Methods</p><p>Pearson χ² test was applied to evaluate the association of MCMs expression with clinicopathologic indicators, and biomarkers for tumor biological behaviors. Kaplan-Meier plots and log-rank tests were used to assess survival analysis, and univariate and multivariate Cox proportional hazard regression models were used to recognize independent prognostic factors.</p><p>Results</p><p>MCM1-10 were generally expressed in PC samples. The levels of some molecules were markedly correlated with that of biomarkers for S phase, proliferation, gemcitabine resistance. And part of these molecules over-expression was significantly associated with indicators of disease progression, such as depth of tumor invasion and lymph node metastasis. Furthermore, MCM2, 4, 6, 8, and 10 over-expression was remarkably associated with shorter disease free survival time, and MCM2, 4,8, and 10 over-expression was associated with shorter overall survival time. Further multivariate analysis suggested that MCM8 was an independent prognostic factor for PC.</p><p>Conclusion</p><p>MCMs abnormal over-expression was significantly associated with PC progression and prognosis. These molecules could be regarded as prognostic and therapeutic biomarkers for PC. The roles of MCMs may be vitally important and the underlying mechanisms need to be furtherinvestigated.</p></div

The relative expression of MCM1-10 in 165 PC samples.

<p>(A) The relative expression of MCM1-5 in 165 PC samples. (B) The relative expression of MCM6-10 in 165 PC samples.</p

Survival outcomes.

<p>Survival outcomes.</p

Clinicopathologic features of the patients with PC.

<p>Clinicopathologic features of the patients with PC.</p

Survival analysis of PC patients correlated with MCM1-10 expression.

<p>(A) The association between MCM1-10 expression and disease free survival time. The higher expression of MCM2, 4, 6, 8, and 10 was significantly associated with shorter disease free survival time. (B) The correlation between MCM1-10 expression and overall survival time. The higher levels of MCM2, 4, 8, and 10 were markedly corrected with poorer outcome.</p

Association between MCMs and biomarkers for tumor biological behaviors.

<p>Association between MCMs and biomarkers for tumor biological behaviors.</p

Additional file 1: of Downregulated miR-98-5p promotes PDAC proliferation and metastasis by reversely regulating MAP4K4

Table S1. All primers involved in this research (5′-3′). (DOCX 13 kb

Association between MCMs expression and clinicopathologic variables.

<p>Association between MCMs expression and clinicopathologic variables.</p

A simplified prognostic score for T-cell large granular lymphocyte leukaemia

T-cell large granular lymphocyte leukaemia (T-LGLL) generally has a favourable prognosis, but a small proportion of patients are facing a relatively short survival time. This study aimed to identify clinical factors associated with survival in patients with T-LGLL and develop a predictive model for guiding therapeutic decision-making. We conducted a retrospective study on 120 patients with T-LGLL. Lasso regression was performed for feature selection followed by univariate and multivariate Cox regression analysis. A decision tree algorithm was employed to construct a model for predicting overall survival (OS) in T-LGLL. The median age of diagnosis for the entire cohort was 59 years, and 76.7% of patients reported disease-related symptoms. After a median follow-up of 75 months, the median OS was not reached. The 5-year OS rate was 82.2% and the 10-year OS rate was 63.8%. Multivariate analysis revealed that an Eastern Cooperative Oncology Group performance status over two and a platelet count below 100 × 109/L were independently associated with worse OS, leading to the development of a simplified decision tree model. The model’s performance was adequate when internally validated. The median OS of the high- and intermediate-risk- risk groups was 43 and 100 months respectively, whereas the median OS of the low-risk group was not reached. Furthermore, we found that immunosuppressive agent-based conventional treatment was unsatisfactory for our high-risk patients. Our model is an easily applicable clinical scoring system for predicting OS in patients with T-LGLL. However, external validation is essential before implementing it widely.</p